Elizabeth Kantor, PhD, MPH

Assistant Attending Epidemiologist

Office Phone





University of Washington

Dr. Elizabeth Kantor’s research centers on understanding how modifiable exposures, such as obesity, drugs, and supplements, relate to cancer risk and survival. Much of Elizabeth’s work has been focused on chemoprevention and understanding the mechanisms by which supplements and drugs may reduce cancer risk.  Elizabeth seeks to address these research questions through use of questionnaire data and biomarker data from a variety of data sources, including a number of epidemiologic cohorts and nationally representative survey data. Before moving to Memorial Sloan Kettering Cancer Center, Elizabeth completed a post-doc at the Harvard School of Public Health, a PhD in Epidemiology at the University of Washington, and an MPH at the University of Michigan.


Navarro SL, Kantor ED, Song X, Milne GL, Lampe JW, Kratz M, White E. Factors Associated with Biomarkers of Systemic Inflammation in the VITamins And Lifestyle Biomarker Study. Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):521-31.

Kantor ED*, Rehm CD*, Haas JS, Chan AT, Giovannucci EL. Trends in Prescription Drug Use among Adults in the United States from 1999-2012. JAMA. 2015. 314(17):1818-31. *Denotes shared first authorship

Kantor ED, Udumyan R, Signorello LB, Giovannucci EL, Montgomery S, Fall K. Late-adolescent body mass index and erythrocyte sedimentation rate in relation to colorectal cancer risk. Gut. 2015 May 18. [Epub ahead of print]

Kantor ED, Lipworth L, Fowke J, Giovannucci EL, Mucci LA, Signorello LB. Statin use and risk of prostate cancer: Results from the Southern Community Cohort Study. Prostate. 2015 Sep;75(13):1384-93.

Hirko KA, Kantor ED, Cohen SS, Blot WJ, Stampfer MJ, Signorello LB. Body mass index in young adulthood, obesity trajectory and premature mortality. Am J Epidemiol. 2015 Sep 1;182(5):441-50.

Navarro SL, White E, Kantor ED, Zhang Y, Rho J, Song X, Milne GL, Lampe PD, Lampe JW. Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and proteomics profiles in healthy humans. PLoS One. 2015; 26;10(2):e0117534.

Kantor ED, Giovannucci EL. Gene-diet interactions and their impact on colorectal cancer risk Curr Nutr Reports. 2015; 4(1):13-21.

Citronberg J, Kantor ED, Potter JD, White E. A prospective study of bowel movement frequency, constipation, and laxative use on colorectal cancer risk. Am J Gasteroenterol. 2014; 109(10): 1640-9.

Kantor ED, Hutter CM, Minnier J, Berndt SI, Brenner H, Caan BJ, Campbell PT, Carlson    CS,   Casey G, Chan AT, Chang-Claude J,  Chanock SJ, Cotterchio M, Du M, Duggan D, Fuchs CS, Giovannucci EL, Gong J, Harrison TA, Hayes RB, Henderson BE, Hoffmeister M, Hopper JL, Jenkins MA, Jiao S, Kolonel LN, Le Marchand L, Lemire M, Ma J, Newcomb PA, Ochs-Balcom HM, Pflugeisen BM, Potter JD, Rudolph A, Schoen RE, Seminara D, Slattery ML, Stelling DL, Thomas F, Thornquist M, Ulrich CM, Warnick GS,  Zanke BW,  Peters U, Hsu L, White E. Gene-environment interaction involving recently identified colorectal cancer susceptibility loci. Cancer Epidemiol Biomarkers Prev. 2014; 23(9):1824-33.

Bell GA, Kantor ED, Lampe JW, Kristal A, Heckbert S, White E. Intake of Long-Chain Omega-3 Fatty Acids from Diet and Supplements in Relation to Mortality. Am J Epidemiol. 2014; 179(6):710-20.

Kantor ED, Lampe JW, Navarro SL, Song X, Milne GL, White E. Associations between Glucosamine and Chondroitin Supplement Use and Biomarkers of Systemic Inflammation. J Altern Complement Med. 2014; 20(6):479-85.

Kantor ED, Lampe JW, Peters U, Vaughan TL, White E. Long-chain omega-3 polyunsaturated fatty acid intake and risk of colorectal cancer. Nutr Cancer. 2014;66(4):716-727.

Kantor ED, Ulrich CM, Owen RW, Schmezer P, Neuhouser ML, Lampe JW, Peters U, Shen DD, Vaughan TL, White E. Specialty supplement use and biologic measures of oxidative stress and DNA damage. Cancer Epidemiol Biomarkers Prev. 2013;22(12):2312-22.

Perrigue MM, Kantor ED, Hastert TA, Patterson R, Potter JD, Neuhouser ML, White E. Eating frequency and colorectal cancer. Cancer Causes Control. 2013;24(12):2107-15.

Kantor ED, Lampe JW, Peters U, Shen DD, Vaughan TL, White E. Use of glucosamine and chondroitin supplements and risk of colorectal cancer. Cancer Causes Control. 2013; 24(6):1137-46.

Kantor ED, Lampe JW, Kratz M, White E. Lifestyle factors and inflammation: associations by body mass index.  PLoS One. 2013; 2;8(7):e67833.

Schairer C, Soliman AS, Omar S, Khaled H, Eissa S, Ben Ayed F, Khalafallahf SW, Ben Ayoub W, Kantor ED, Merajver S, Swain SM, Gail M, Brown LM. Assessment of Diagnosis of Inflammatory Breast Cancer Cases at Two Cancer Centers in Egypt and Tunisia.  Cancer Med. 2013; 2(2):178-84.

Jiao S, Hsu L, Berndt S, Bézieau S, Brenner H, Buchanan D, Caan BJ, Campbell PT, Carlson CS, Casey G, Chan AT, Chang-Claude J, Chanock S, Conti DV, Curtis KR, Duggan D, Gallinger S, Gruber SB, Harrison TA, Hayes RB, Henderson BE, Hoffmeister M, Hopper JL, Hudson TJ, Hutter CM, Jackson RD, Jenkins MA, Kantor ED, Kolonel LN, Küry S, Le Marchand L, Lemire M, Newcomb PA, Potter JD, Qu C, Rosse SA, Schoen RE, Schumacher FR, Seminara D, Slattery ML, Ulrich CM, Zanke BW, Peters U. Genome-wide search for gene-gene interactions in colorectal cancer. PLoS One. 2012; 7(12):e52535.

Kantor ED, Lampe JW, Vaughan TL, Peters U, Rehm CD, White E. Association between use of specialty dietary supplements and C-reactive protein concentrations. Am J Epidemiol. 2012; 176(11):1002-13.

Soliman AS, Kleer CG, Mrad K, Karkouri M, Omar S, Khaled HM, Benider AL, Ayed FB, Eissa SS, Eissa MS, McSpadden EJ, Lo AC, Toy K, Kantor ED, Xiao Q, Hampton C, Merajver SD. Inflammatory breast cancer in North Africa: Comparison of clinical and molecular epidemiologic characteristics of patients from Egypt, Tunisia, and Morocco. Breast Dis. 2012; 33(4):159-69.

Bell GA, Kantor ED, Lampe JW, Shen DD, White E.  Use of glucosamine and chondroitin in relation to mortality. Eur J Epidemiol. 2012; 27(8):593-603.

Kantor ED, Onstad L, Blount PL, Reid BJ, Vaughan TL. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 2012; 21(3):456-61.